185 related articles for article (PubMed ID: 20736944)
1. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.
Faupel-Badger JM; Sherman ME; Garcia-Closas M; Gaudet MM; Falk RT; Andaya A; Pfeiffer RM; Yang XR; Lissowska J; Brinton LA; Peplonska B; Vonderhaar BK; Figueroa JD
Br J Cancer; 2010 Sep; 103(7):1097-102. PubMed ID: 20736944
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland.
Nyante SJ; Faupel-Badger JM; Sherman ME; Pfeiffer RM; Gaudet MM; Falk RT; Andaya AA; Lissowska J; Brinton LA; Peplonska B; Vonderhaar BK; Chanock S; Garcia-Closas M; Figueroa JD
Breast Cancer Res; 2011 Apr; 13(2):R42. PubMed ID: 21470416
[TBL] [Abstract][Full Text] [Related]
3. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women.
Eliassen AH; Tworoger SS; Hankinson SE
Int J Cancer; 2007 Apr; 120(7):1536-41. PubMed ID: 17211859
[TBL] [Abstract][Full Text] [Related]
4. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort.
Tikk K; Sookthai D; Johnson T; Rinaldi S; Romieu I; Tjønneland A; Olsen A; Overvad K; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Pala V; Tumino R; Rosso S; Panico S; Agudo A; Menéndez V; Sánchez MJ; Amiano P; Huerta Castaño JM; Ardanaz E; Bueno-de-Mesquita HB; Monninkhof E; Onland-Moret C; Andersson A; Sund M; Weiderpass E; Khaw KT; Key TJ; Travis RC; Gunter MJ; Riboli E; Dossus L; Kaaks R
Ann Oncol; 2014 Jul; 25(7):1422-1428. PubMed ID: 24718887
[TBL] [Abstract][Full Text] [Related]
5. Serum sex hormone levels in pre- and postmenopausal breast cancer patients.
Ho CC; Rohaizak M; Zulkifli SZ; Siti-Aishah MA; Nor-Aini U; Sharifah-Noor-Akmal SH
Singapore Med J; 2009 May; 50(5):513-8. PubMed ID: 19495523
[TBL] [Abstract][Full Text] [Related]
6. Plasma prolactin concentrations and risk of postmenopausal breast cancer.
Tworoger SS; Eliassen AH; Rosner B; Sluss P; Hankinson SE
Cancer Res; 2004 Sep; 64(18):6814-9. PubMed ID: 15375001
[TBL] [Abstract][Full Text] [Related]
7. Increased hypothalamic dopaminergic tone only in early parous women with either malignant or benign breast tumors.
Ortega-González C; Parra A; Barra R; Aranda C; Ramírez D; Di Castro P; Castro I; Zambrana M; Coria I
Endocr Pract; 2002; 8(2):89-95. PubMed ID: 11942771
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.
Lee SA; Haiman CA; Burtt NP; Pooler LC; Cheng I; Kolonel LN; Pike MC; Altshuler D; Hirschhorn JN; Henderson BE; Stram DO
BMC Med Genet; 2007 Dec; 8():72. PubMed ID: 18053149
[TBL] [Abstract][Full Text] [Related]
9. 24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment.
Kalleinen N; Polo-Kantola P; Irjala K; Porkka-Heiskanen T; Vahlberg T; Virkki A; Polo O
J Clin Endocrinol Metab; 2008 May; 93(5):1655-61. PubMed ID: 18319308
[TBL] [Abstract][Full Text] [Related]
10. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women.
Hankinson SE; Willett WC; Michaud DS; Manson JE; Colditz GA; Longcope C; Rosner B; Speizer FE
J Natl Cancer Inst; 1999 Apr; 91(7):629-34. PubMed ID: 10203283
[TBL] [Abstract][Full Text] [Related]
11. Risk Factor Analysis for Breast Cancer in Premenopausal and Postmenopausal Women of Punjab, India.
Kour A; Sharma S; Sambyal V; Guleria K; Singh NR; Uppal MS; Manjari M; Sudan M; Kukreja S
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3299-3304. PubMed ID: 31759352
[TBL] [Abstract][Full Text] [Related]
12. Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study.
Tikk K; Sookthai D; Fortner RT; Johnson T; Rinaldi S; Romieu I; Tjønneland A; Olsen A; Overvad K; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopoulou A; Lagiou P; Trichopoulos D; Masala G; Krogh V; Tumino R; Ricceri F; Mattiello A; Agudo A; Menéndez V; Sánchez MJ; Amiano P; Chirlaque MD; Barricarte A; Bueno-de-Mesquita HB; Monninkhof EM; Onland-Moret NC; Andresson A; Sund M; Weiderpass E; Khaw KT; Key TJ; Travis RC; Merritt MA; Riboli E; Dossus L; Kaaks R
Breast Cancer Res; 2015 Mar; 17(1):49. PubMed ID: 25887963
[TBL] [Abstract][Full Text] [Related]
13. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.
Tworoger SS; Sluss P; Hankinson SE
Cancer Res; 2006 Feb; 66(4):2476-82. PubMed ID: 16489055
[TBL] [Abstract][Full Text] [Related]
14. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland.
Faupel-Badger JM; Duggan MA; Sherman ME; Garcia-Closas M; Yang XR; Lissowska J; Brinton LA; Peplonska B; Vonderhaar BK; Figueroa JD
Horm Cancer; 2014 Feb; 5(1):42-50. PubMed ID: 24249584
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
Tworoger SS; Eliassen AH; Sluss P; Hankinson SE
J Clin Oncol; 2007 Apr; 25(12):1482-8. PubMed ID: 17372279
[TBL] [Abstract][Full Text] [Related]
16. Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study.
Zhang X; Rice M; Tworoger SS; Rosner BA; Eliassen AH; Tamimi RM; Joshi AD; Lindstrom S; Qian J; Colditz GA; Willett WC; Kraft P; Hankinson SE
PLoS Med; 2018 Sep; 15(9):e1002644. PubMed ID: 30180161
[TBL] [Abstract][Full Text] [Related]
17. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
18. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA; Borofsky ND; Massardo S; Orentreich N
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
[TBL] [Abstract][Full Text] [Related]
20. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
